Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.

ABSTRACT:

Background

Multiple sclerosis is the most common demyelinating disease of the central nervous system with serious social and economic burden. Siponimod is a sphingosine-1-phosphate receptor agonist, and clinical trials in the past decade have shown good prospects for the treatment of multiple sclerosis. But there is a lack of comprehensive understanding of the dose-effect relationship and safety in different subtypes of multiple sclerosis at present.

Methods

We will perform a systematic review and meta-analysis of clinical randomized controlled trials to evaluate the efficacy and safety of siponimod in multiple sclerosis. We will search PubMed, EMBASE, Cochrane Library, Clinical Trials, Cochrane Central Register of Controlled Trials (CENTRAL) using a comprehensive strategy.

SUBMITTER: Song Y 

PROVIDER: S-EPMC6716697 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature